Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792257 · ClinicalTrials.gov registry record · Phase 2
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT02792257: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT02792257 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02792257, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the AD course. One of the most troubling of these symptoms is agitation (Agit-AD), typified by a variety of problem behaviors including combativeness, yelling, pacing, lack of cooperation with care, insomnia, and restlessness. There is a great need for better interventions that target Agit-AD, a major source of patient disability as well as caregiver burden and stress, particularly in the case of moderate to severe agitation. This pilot trial could open the door to "re-purposing" Dronabinol (Marinol®) as a novel and safe treatment for Agit-AD with significant public health impact.
Interventions
- DRUG Placebo
- DRUG Dronabinol (Marinol®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02792257
The ClinicalTrials.gov registry entry for NCT02792257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02792257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02792257 about?
NCT02792257 is a clinical study titled "Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease". Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the AD course. One of the most troubling of these symptoms is agitation (A...
What is the current status of trial NCT02792257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-03-01. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT02792257?
The interventions under investigation include: Placebo (DRUG), Dronabinol (Marinol®) (DRUG).
Who is sponsoring clinical trial NCT02792257?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.